Prime Medicine holds routine annual meeting, elects two directors through 2029

Filed June 8, 2026 · Period ending June 5, 2026 · ~1 min read

Key Changes

• low

  Michael Kelly and David Schenkein elected as Class I Directors for three-year terms ending 2029. Schenkein received notably higher withheld votes (22.6M vs 3M) but both passed comfortably.

  Item 5.07 verify on EDGAR →
• low

  Shareholders ratified PricewaterhouseCoopers LLP as independent auditor for 2026 with 99.7% approval (140M for, 101K against).

  Item 5.07 verify on EDGAR →